
Upgrades
According to Brookline Capital, the prior rating for Intellia Therapeutics Inc (NASDAQ:NTLA) was changed from Hold to Buy. In the fourth quarter, Intellia Therapeutics showed an EPS of $1.09, compared to $0.69 from the year-ago quarter. The stock has a 52-week-high of $202.73 and a 52-week-low of $43.86. At the end of the last trading period, Intellia Therapeutics closed at $65.04.